Aquestive Therapeutics (NASDAQ:AQST) Stock: Insider Daniel Barber Sells 25,000 Shares

Aquestive Therapeutics, Inc. (NASDAQ:AQST) CEO Daniel Barber sold 25,000 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $4.22, for a total value of $105,500.00. Following the completion of the transaction, the chief executive officer directly owned 627,317 shares of the company’s stock, valued at $2,647,277.74. This represents a 3.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Barber also recently made the following trade(s):

• On Tuesday, September 15th, Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock. The shares were sold at an average price of $4.82, for a total value of $120,500.00.

Aquestive Therapeutics Stock Down 6.9%

AQST stock opened at $3.78 on Friday. Aquestive Therapeutics, Inc. has a 52-week low of $2.93 and a 52-week high of $7.55. The stock’s 50 day moving average is $4.74 and its two-hundred day moving average is $4.35. The company has a market capitalization of $474.44 million, a PE ratio of -5.82 and a beta of 1.49.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The business had revenue of $13.82 million during the quarter, compared to the consensus estimate of $11.42 million. As a group, sell-side analysts anticipate that Aquestive Therapeutics, Inc. will post -0.50 EPS for the current year.

More Aquestive Therapeutics News

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: The FDA accepted Aquestive’s resubmitted New Drug Application for Anaphylm, its investigational sublingual film for severe allergic reactions and anaphylaxis. The filing was deemed complete, with a PDUFA action date of March 16, 2027. If approved, Anaphylm could become the first oral rescue treatment for anaphylaxis, significantly expanding AQST’s commercial opportunity. Aquestive Therapeutics Announces FDA Acceptance of Anaphylm NDA Resubmission
• Positive Sentiment: The resubmission reportedly includes improved human-factors data showing a substantial reduction in packaging and administration errors, addressing previous FDA concerns. One analyst upgraded AQST to Buy and projected potential Anaphylm revenue exceeding $250 million annually by 2030, although competition and reimbursement remain risks. Aquestive FDA Acceptance of Anaphylm Resubmission Makes for Rating Upgrade
• Neutral Sentiment: AQST CEO Daniel Barber sold 25,000 shares for approximately $105,500, reducing his direct position by 3.83%. The sale occurred under a pre-arranged Rule 10b5-1 plan, which lessens its significance as a discretionary bearish signal. SEC Insider Transaction Filing
• Negative Sentiment: Options trading was unusually defensive, with investors purchasing 11,658 put options—about 390% above typical volume—suggesting increased hedging or bearish speculation around AQST.

Analyst Upgrades and Downgrades

AQST has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price target on shares of Aquestive Therapeutics in a research note on Thursday, September 10th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Thursday. Finally, Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.60.

Institutional Trading of Aquestive Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AQST. Sugar Maple Asset Management LLC lifted its holdings in Aquestive Therapeutics by 5.9% during the 1st quarter. Sugar Maple Asset Management LLC now owns 58,060 shares of the company’s stock worth $241,000 after buying an additional 3,210 shares during the last quarter. International Assets Investment Management LLC grew its position in shares of Aquestive Therapeutics by 27.0% in the 1st quarter. International Assets Investment Management LLC now owns 22,895 shares of the company’s stock worth $95,000 after acquiring an additional 4,870 shares in the last quarter. Quantinno Capital Management LP grew its position in shares of Aquestive Therapeutics by 52.8% in the 1st quarter. Quantinno Capital Management LP now owns 18,014 shares of the company’s stock worth $75,000 after acquiring an additional 6,221 shares in the last quarter. Engineers Gate Manager LP increased its holdings in shares of Aquestive Therapeutics by 20.5% in the 2nd quarter. Engineers Gate Manager LP now owns 49,879 shares of the company’s stock valued at $207,000 after acquiring an additional 8,496 shares during the last quarter. Finally, Corsair Capital Management L.P. increased its holdings in shares of Aquestive Therapeutics by 16.7% in the 1st quarter. Corsair Capital Management L.P. now owns 70,000 shares of the company’s stock valued at $290,000 after acquiring an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a pharmaceutical company that develops and commercializes medicines using proprietary drug-delivery technologies, including its PharmFilm platform. The company’s oral and buccal films are designed to dissolve in the mouth and may provide alternatives to conventional tablets, capsules, injections, or liquid formulations.

Aquestive’s commercial and partnered products have included treatments for neurological conditions. Its portfolio includes Libervant (diazepam buccal film) for seizure clusters, Exservan (riluzole oral film) for amyotrophic lateral sclerosis, and Sympazan (clonazepam oral film) for certain seizure disorders.